Shenzhen Hepalink Pharma Invests $60M In TPG Biotech Fund

Chinese drug maker Shenzhen Hepalink Pharmaceutical plans to invest US$60 million in TPG Biotechnology Partners V, L.P., which mainly targets biomedical technology and life science companies, the company announced in a statement (in Chinese).

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets